2 hours ago
1
designer491
BridgeBio Pharma (NASDAQ:BBIO) has accused its rivals, Pfizer (NYSE:PFE) and Alnylam (NASDAQ:ALNY), of using questionable tactics to promote their products in the multibillion-dollar drug market for a rare heart disorder called transthyretin cardiac amyloidosis, Bloomberg News reported.
All three companies
English (US) ·